Efficacy and Safety of the Two-Drug Regimen Dolutegravir–Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial | Publicación